Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients
Rivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH calibrated anti-Xa assays at VTE prophylactic dos...
Saved in:
Main Authors: | Kaitlin Blotske PharmD, Toral Patel PharmD, BCPS, Toby Trujillo PharmD, FCCP, FAHA, BCPS, Matthew Marlar MLS (ASCP), Stuart Lind MD, Henry Kramer MD, Kathryn Hassell MD, Tyree H. Kiser PharmD, FCCM, FCCP, BCCCP, BCPS |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/10760296251319961 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
by: Tahuanty A. Pena, MD, MS, et al.
Published: (2025-02-01) -
Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil
by: Daniel Lachant, DO, et al.
Published: (2025-05-01) -
Hydroxocobalamin for the treatment of vasoplegia after lung transplantation: A case series
by: Anh Nguyen, MD, PhD, et al.
Published: (2025-02-01) -
Lung transplant outcomes for recipients with alpha-1 antitrypsin deficiency, by use of alpha-1 antitrypsin augmentation therapy
by: Atharv V. Oak, MEng, et al.
Published: (2025-02-01) -
Gestational weight gain and increased risk of cesarean delivery across body mass index categoriesAJOG Global Reports at a Glance
by: Pearl A. McElfish, PhD, et al.
Published: (2025-02-01)